- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00378014
Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy
19 janvier 2015 mis à jour par: Novartis Pharmaceuticals
Presentation of Renal Function in Liver Transplant Recipients With Certican Therapy: PROTECT Study A Twelve-month, Multicenter, Randomized, Open-label Study of Safety, Tolerability and Efficacy of Certican-based Regimen Versus Calcineurin Inhibitor-based Regimen in de Novo Liver Transplant Recipients
The study is designed to show that everolimus initiation together with reduction and thereafter discontinuation of calcineurin inhibitor (CNI) will improve significantly renal function in de novo liver transplant recipients as compared to continuation of CNI-based treatment.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Réel)
276
Phase
- Phase 3
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
-
Berlin, Allemagne, 13353
- Novartis Investigative Site
-
Essen, Allemagne, 45147
- Novartis Investigative Site
-
Frankfurt, Allemagne, 60590
- Novartis Investigative Site
-
Hamburg, Allemagne, 20246
- Novartis Investigative Site
-
Hannover, Allemagne, 30625
- Novartis Investigative Site
-
Heidelberg, Allemagne, 69120
- Novartis Investigative Site
-
Jena, Allemagne, 07740
- Novartis Investigative Site
-
Muenster, Allemagne, 48149
- Novartis Investigative Site
-
Regensburg, Allemagne, 93053
- Novartis Investigative Site
-
Tübingen, Allemagne, 72076
- Novartis Investigative Site
-
-
-
-
-
Innsbruck, L'Autriche, A-6020
- Novartis Investigative Site
-
Wien, L'Autriche, A-1090
- Novartis Investigative Site
-
-
-
-
-
Groningen, Pays-Bas, 9713 GZ
- Novartis Investigative Site
-
Rotterdam, Pays-Bas, 3015 CE
- Novartis Investigative Site
-
-
-
-
-
Genève, Suisse, 1211
- Novartis Investigative Site
-
Zurich, Suisse, 8091
- Novartis Investigative Site
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans à 70 ans (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- Males or females 18 - 70 years old
- Liver transplant recipient (living or deceased donor)
- Patients in whom an allograft biopsy will not be contraindicated
Exclusion Criteria:
- Recipients of multiple solid organ transplants or patients that have already received a transplant in the past
- HCV positive patients who need an active anti-viral treatment (HCV- positive patients without active antiviral treatment are allowed)
- HIV positive patients
- Patients who are breast feeding
- Patients with a current severe systemic infection
- Presence of any hypersensitivity to drugs similar to Certican® (e.g. macrolides)
- Preexisting (i.e. not related to CNI-damage) renal dysfunction that, according to the judgment of the investigator, will not significantly improve after transplantation (i.e., for example, patients that are expected to have a cGFR below 50ml/min at 4 weeks post transplantation)
- Patients that have received Simulect prior to this study.
- Other protocol-defined inclusion/exclusion criteria may apply.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Everolimus
Basiliximab plus everolimus-based immunosuppressive regimen following the reduction and cessation of initial CNI regimen plus optional steroids according to local best practice
|
All patients who met the eligibility criteria were treated with 2 doses of basiliximab on Day 0 (transplantation) and Day 4.
Autres noms:
Patients who met the screening eligibility received CNI-based immunosuppressive therapy for 1 month.
Then at week 4 (or week 8 at maximum), patients randomized to the CNI arm continued on CNI-based immunosuppressive therapy.
|
Comparateur actif: Calcineurin Inhibitor (CNI)
Basiliximab plus CNI-based immunosuppressive regimen according to local best practice plus optional steroids according to local best practice
|
All patients who met the eligibility criteria were treated with 2 doses of basiliximab on Day 0 (transplantation) and Day 4.
Autres noms:
Patients who met the screening eligibility received CNI-based immunosuppressive therapy for 1 month.
Then at week 4 (or week 8 at maximum), patients randomized to the CNI arm continued on CNI-based immunosuppressive therapy.
Start dose of everolimus was 1.5 mg in the morning followed by 1.5 mg in the evening.
After one week, the dose was adjusted to achieve trough levels between 5-12 ng/mL.
Once trough levels were above 5ng/mL, the CNI dose was reduced to 70%.
At week 8 post-baseline (latest at week 16 post baseline), CNI was completely discontinued.
For patients receiving Ciclosporin A (CiA) as CNI, the everolimus dosage was adjusted to achieve a trough level of 8-12 ng/mL, prior to discontinuation of CiA.
After discontinuation of CNI, everolimus was maintained at a trough level of 5-12 ng/mL.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Calculated Glomerular Filtration Rate (cGFR)
Délai: Month 11
|
This outcome measure evaluated renal function by assessing the calculated GFR based on the Cockcroft-Gault formula.
|
Month 11
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Incidence of Efficacy Failure
Délai: Month 11
|
Efficacy failure was defined as the composite endpoint of biopsy-proven acute rejection (BPAR), graft loss, death, lost to follow-up (from any reason), whichever occurred first.
Incidence of efficacy failure was estimated using crude rate estimation (relative frequency).
|
Month 11
|
Incidence of the Need for a Change in the Immunosuppressive Regimen
Délai: Month 11
|
The incidence of any changes in the immunosuppressive regimen other than allowed in the study protocol (for example, introduction of Mycophenolic acid (MPA) or sirolimus) was estimated using crude rate estimation (relative frequency).
|
Month 11
|
Incidence of Renal Deterioration
Délai: Baseline, Month 11
|
Renal deterioration was defined as a decrease by ≥25% in the cGFR compared to baseline and confirmed by one consecutive measurement.
The analysis of this outcome measure was omitted because of missing relevance.
|
Baseline, Month 11
|
Renal Function (cGFR)
Délai: Month 5
|
This outcome measure evaluated renal function by assessing the calculated GFR based on the Cockcroft-Gault formula.
|
Month 5
|
Incidence of Treated BPAR
Délai: Month 11
|
The incidence of treated BPAR was estimated using crude rate estimation (relative frequency).
|
Month 11
|
Patient and Graft Survival
Délai: Month 11
|
Patient survival was defined as the time from date of randomization to date of death from any cause.
If a patient was not known to have died, patient survival was censored as the date of last contact.
Graft survival was defined as the time from the date of randomization to the date of graft loss.
If a patient was not known to suffer from a graft loss or died without graft loss, time to graft loss was censored with date of last contact or date of death, respectively.
Patient and graft survival were analyzed using the Kaplan Meier method.
|
Month 11
|
Hepatitis C Virus (HCV) Replication in HCV-positive Patients
Délai: Baseline, Month 5
|
HCV ribonucleic acid (RNA) was measured by real time reverse transcriptase polymerase chain reaction (PCR; copies per mL).
|
Baseline, Month 5
|
Number of Patients Who Experienced Adverse Events, Serious Adverse Events and Death
Délai: From randomization to Month 11
|
Patients with all (serious and non-serious) adverse events, serious adverse events and death were reported.
|
From randomization to Month 11
|
Number of Patients Who Experienced Adverse Events, Serious Adverse Events and Death
Délai: Month 12 to Month 59 post-baseline
|
Patients with all (serious and non-serious) adverse events, serious adverse events and death were reported.
|
Month 12 to Month 59 post-baseline
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 août 2006
Achèvement primaire (Réel)
1 janvier 2013
Achèvement de l'étude (Réel)
1 janvier 2013
Dates d'inscription aux études
Première soumission
15 septembre 2006
Première soumission répondant aux critères de contrôle qualité
18 septembre 2006
Première publication (Estimation)
19 septembre 2006
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
6 février 2015
Dernière mise à jour soumise répondant aux critères de contrôle qualité
19 janvier 2015
Dernière vérification
1 janvier 2015
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CRAD001HDE10
- 2005-002920-32
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Transplantation hépatique
-
Abramson Cancer Center of the University of PennsylvaniaRetiréPatients cancéreux subissant une greffe de cellules souches (RCT of ACP for Transplant)
Essais cliniques sur basiliximab
-
Drexel University College of MedicineNovartisRésiliéPhase terminale de la maladie rénaleÉtats-Unis
-
Asan Medical CenterInconnueTransplantation rénaleCorée, République de
-
McGill University Health Centre/Research Institute...Inconnue
-
Fort Worth Clinical Sciences Working GroupTCU and UNTHSC School of MedicinePas encore de recrutementInfection par le SRAS-CoV2 | Tempête de cytokines | Maladie respiratoire aiguë SARS-CoV-2
-
Gary Archer Ph.D.National Cancer Institute (NCI)Complété
-
The First Affiliated Hospital of Soochow UniversityThe Second People's Hospital of Huai'an; Soochow Hopes Hematonosis HospitalRecrutement
-
University Health Network, TorontoNovartisComplétéEmphysème | MPOC | Déficit en Alpha-1 AntitrypsaneCanada
-
Fuzhou General HospitalInconnueTransplantation rénale d'un parent vivantChine
-
Gang ChenChanghai Hospital; First Affiliated Hospital, Sun Yat-Sen University; The First... et autres collaborateursComplétéRejet de greffe de rein | Maladie rénale pédiatriqueChine
-
Nationwide Children's HospitalRésiliéMaladie du greffon contre l'hôte | Maladie aiguë de GVH | GVHD réfractaire aux stéroïdesÉtats-Unis